<DOC>
	<DOCNO>NCT02735629</DOCNO>
	<brief_summary>The study investigation ass capacity ascend dos CX1739 antagonize respiratory depressive effect remifentanil . The study also investigate whether ascend dos CX1739 reduce analgesic effect remifentanil alter BIS measure sedation evaluate safety CX1739 use conjunction remifentanil .</brief_summary>
	<brief_title>Antagonism Opioid-Induced Respiratory Depression CX1739 With Preservation Opioid Analgesia</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<criteria>To eligible trial , subject must meet following criterion : 1 . Males 18 50 year age , inclusive 2 . Body mass index 18.0 30.0 kg/m2 , inclusive , use formula : weight ( kg ) /height ( ) 2 3 . Healthy , determine medical history , physical examination include vital sign , clinical laboratory test result 4 . American Society Anesthesiologists Physical Status Classification 1 5 . Willing able provide voluntary , write informed consent If subject meet follow criterion , enrol study : 1 . History chronic illness evidence clinically significant organic psychiatric disease medical history physical examination , opinion principal investigator ( PI ) , would confound study result present risk subject 2 . Acute illness within 2 week dose 3 . History clinically significant pulmonary condition ( eg , asthma ) within last 2 year require admission hospital 4 . Previous diagnosis obstructive sleep apnea base polysomnography 5 . Currently use prescription medication use within last 30 day 6 . Laboratory value ( clinical chemistry , hematology , urinalysis ) outside laboratory reference range consider clinically significant ( NOTE : event parameter lie outside normal range , sample may repeat ; value accept lie within normal range ) 7 . Presence QT interval correct &gt; 440 msec ECG 8 . Resting HR awake &lt; 45 &gt; 90 beats/minute 9 . History daily use tobacco nicotinecontaining product within 1 year study entry positive cotinine test screen subsequent study visit 10 . History allergic hypersensitivity ampakines ( CX717 , CX1739 ) , remifentanil , naloxone , component formulation ; history multiple drug allergy 11 . History current evidence abuse drug substance , licit illicit , include alcohol ; positive urine drug screen ( UDS ) drug abuse screen 12 . Inability understand protocol requirement ; instruction ; studyrelated restriction ; nature , scope , possible consequence study 13 . Unlikely complete study , eg , inability return followup visit 14 . Participation another study investigational drug 3 month precede study 15 . Blood plasma donation 500 mL month randomization 50 mL 2 week randomization</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>